Kenya Pharmaceuticals and Healthcare Report Q4 2017
Within the wider East Africa region, Kenya's pharmaceutical market will be viewed asa particularly attractive investment destination by international drugmakers given its favourable economicgrowth outlook and increasing chronic disease burden. Strict controls of illegal drug dealings will have asignificant impact on drugs sales within the country. Though it does not yet cover the majority of thecountry's population, the innovative measures undertaken within the health insurance sector will result inincreased pharmaceuticals and healthcare sales within the country.
Headline Expenditure Projections
Pharmaceuticals: KES83.83bn (USD826mn) in 2016 to KES95.25bn (USD914mn) in 2017; 13.6%growth in local currency terms and 10.7% in US dollar terms. Forecast unchanged from previousquarter.
Healthcare: KES378.56bn (USD3.72bn) in 2015 to KES417.26bn (USD4.00bn) in 2016; 10.2% growthin local currency terms and 7.4% in US dollar terms. Forecast unchanged from previous quarter.
Risk/ Reward Index
Sub-Saharan Africa is a region with high variability of market attractiveness for innovative drugmakers.While certain markets hold significant opportunities for the commercialisation of pharmaceuticals, theregion itself lags behind global standards in all areas given its underdeveloped nature. As such, it is vitalthat companies appreciate the varying levels of investment risks and rewards that are present in the marketsin Sub-Saharan Africa. BMI's Innovative Pharmaceuticals
, which provides a globallycomparative and numerically based assessment of a market's attractiveness for companies looking to launcha high-value drug, was established to address this.